SHANGHAI – Suzhou Ribo Life Science Co. Ltd., a Chinese siRNA drug company established in 2007, has raised $20 million in venture capital financing. The round was led by Legend Capital and joined by GGV Capital and Panlin Capital with the participation of the Kunshan RNAi Institute and Legend Star.
SHANGHAI – Wechat, China's version of Twitter, broke out in excitement and some surprise when the Nobel prize went public this week. It took a modest researcher with no PhD in her eighth decade to land China's first Nobel Prize for Medicine or Physiology. (See BioWorld Today, Oct. 6, 2015.)
SHANGHAI – Ark Biosciences Inc. successfully completed a phase I trial for AK0529, an oral drug designed to treat respiratory syncytial virus (RSV), a common virus that can be deadly in premature infants, children and the elderly by infecting the lungs and respiratory tract.
SHANGHAI – Ark Biosciences Inc. successfully completed a phase I trial for AK0529, an oral drug designed to treat respiratory syncytial virus (RSV), a common virus that can be deadly in premature infants, children and the elderly by infecting the lungs and respiratory tract.
SHANGHAI – Zai Lab Ltd., located in the well-known Zhangjiang Hi-tech Park, has inked a deal with UCB SA, of Brussels, licensing global rights to its first large molecule asset, set to go into phase I trials in 2016.
SHANGHAI – Zai Lab Ltd., located in the well-known Zhangjiang Hi-tech Park, has inked a deal with UCB SA, of Brussels, licensing global rights to its first large molecule asset, set to go into phase I trials in 2016.
SHANGHAI – Sciclone Pharmaceuticals Inc. is one of a few U.S.-listed specialty pharma companies almost exclusively focused on the China market. CEO Friedhelm Blobel sits in Foster City, Calif. – to be close to investors and shareholders – but he frequently finds himself on a plane to China, the main market for Sciclone’s oncology, infectious disease and cardiovascular therapies.
SHANGHAI – Hangzhou, China-based Ascletis Inc. received $35 million in venture capital investment and kicked off a Taiwan phase II trial for its interferon-free hepatitis C regimen.
